Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients
Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients
Stopping aspirin after 1 month DAPT in ACS patients after stenting
Stopping aspirin after 1 month DAPT in ACS patients after stenting
Head-to-head comparison of two TAVR devices in patients with aortic stenosis and small aortic annuli
Head-to-head comparison of two TAVR devices in patients with aortic stenosis and small aortic annuli
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
Beyond BeAT-HF: Integrating Barostim into a Comprehensive HF Program
Beyond BeAT-HF: Integrating Barostim into a Comprehensive HF Program
Allergic Reactions and Cardiac Concerns: Exploring the Heart Disease Link
Allergic Reactions and Cardiac Concerns: Exploring the Heart Disease Link
Active Aging: Preventing Heart Failure in Older Women with Exercise
Active Aging: Preventing Heart Failure in Older Women with Exercise
Improving CKD Patient Outcomes with SGLT2 Inhibitors
Improving CKD Patient Outcomes with SGLT2 Inhibitors
Cardiovascular Disease in T2D: Researchers Identify Potential Therapeutic Target for Underlying Cause
Cardiovascular Disease in T2D: Researchers Identify Potential Therapeutic Target for Underlying Cause
New Guidance on Neurodevelopment Outcomes in Patients with Heart Defects
New Guidance on Neurodevelopment Outcomes in Patients with Heart Defects
AHA Identifies CKM Syndrome: A First Step in Managing Patients with CVD
AHA Identifies CKM Syndrome: A First Step in Managing Patients with CVD
CKM Syndrome Linked to Heart, Kidney, and Metabolic Diseases
CKM Syndrome Linked to Heart, Kidney, and Metabolic Diseases